X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 99% Over Last Week

Simply Wall StDec 12 06:26 ET

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

X4 PharmicalsDec 4 00:00 ET

Express News | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 3 16:05 ET

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 PharmicalsDec 3 00:00 ET

B.Riley Financial Maintains X4 Pharmaceuticals(XFOR.US) With Hold Rating, Cuts Target Price to $0.5

Moomoo NewsNov 19 03:36 ET · Ratings

B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating

MT NewswiresNov 18 09:01 ET · Ratings